Summary
Dr. Owen Muir uses a meta-article format to both teach his writing process and discuss a new study on TMS for suicidal ideation. He shares his workflow for producing prolific healthcare content, including using Google Scholar alerts, tracking reader engagement data, and finding new angles on familiar topics. The study he covers, from Spain, examined 104 adults treated with bilateral rTMS targeting the dorsolateral prefrontal cortex, finding 61% remission of suicidal ideation, 41% remission for depression, and 33% for anxiety, all statistically significant. He notes the irony that US insurance has historically excluded suicidal ideation from TMS coverage despite this evidence.
Key Points
- A Spanish study of 104 adults showed 61% remission of suicidal ideation with bilateral rTMS targeting the DLPFC
- The same study found 41% remission for depression and 33% for anxiety, all with p < 0.001
- Both active and passive suicidal ideation groups improved with TMS treatment
- US insurance plans historically excluded acute suicidal ideation from TMS coverage
- The standard treatment course involved 30 sessions of bilateral rTMS
- Different brain circuits exist for anxiosomatic depression versus other subtypes, enabling targeted treatment
- Dr. Muir shares his content creation workflow as a model for prolific medical writing
Key Moments
TMS for suicidal ideation shows 61% remission
Dr. Muir highlights a new study showing TMS can rapidly relieve suicidal ideation in depressed patients, a finding that challenges US insurance exclusions.
"The article is titled, Rapid Relief of Suicidal Ideation via Transcranial Magnetic Stimulation in Depressed Patients. This is completely up my alley."
Remission rates across depression, anxiety, and suicidal ideation
The study data reveals impressive remission rates across multiple conditions treated with bilateral rTMS targeting the DLPFC: 61% for suicidal ideation, 41% for depression, and 33% for anxiety.
"Remission was achieved in 41% for depression, 33% for anxiety, and 61% for suicidal ideation. Both active and passive SI groups improved."
Insurance paradox of excluding suicidal patients from TMS
Dr. Muir highlights the irony that US insurance plans have excluded acutely suicidal patients from TMS coverage, despite emerging data showing it is particularly effective for this population.
"For years, many insurance plans in the US excluded acute suicidal ideation from the coverage of transcranial magnetic stimulation, which makes this data more remarkable for those of us here in the US."
